Immunotherapy Combination Offers a Better Chance at Longer Survival for Patients with Metastatic Kidney Cancer

By Andrew J. Roth,

Monday, April 16, 2018

MSK medical oncologist Robert Motzer
Summary

The combination of two immunotherapies outperformed a targeted therapy with regard to overall survival in a phase III study of untreated patients with metastatic renal cell carcinoma (a type of kidney cancer).

Update: On April 16, 2018, the FDA approved the combination of nivolumab and ipilimumab for the treatment of people with poor- and intermediate-risk advanced renal cell carcinoma.

On March 21, 2018, new data from this study were published in the New England Journal of Medicine, further proving the efficacy of the ipilimumab and nivolumab combination. The trial included 1,096 total patients with metastatic renal cell carcinoma, and researchers found that overall survival favored the immunotherapy combination, with an 18-month overall survival rate of 78% compared with 68% with sunitinib alone.


Original post: For years, oncologists had very few choices to treat patients with metastatic renal cell carcinoma. Their primary options were two types of immunotherapy drugs, interferon-alpha and interleukin-2, then the targeted therapy sunitinib (Sutent®), which was approved in 2006. Since then, sunitinib has remained the standard of care as initial treatment for this disease.

People with metastatic renal cell carcinoma may soon have a new option to treat their disease and extend their life.

On September 7, 2017, Bristol-Myers Squibb announced that the combination of the immunotherapies ipilimumab (Yervoy®) and nivolumab (Opdivo®) extended survival for people with metastatic renal cell carcinoma in a phase III trial. The study, led by MSK medical oncologist Robert Motzer, compared the combination of those immunotherapies against sunitinib alone in patients with the disease who had not yet received treatment.

At the European Society for Medical Oncology (ESMO) Congress on September 10, 2017, oncologist Bernard Escudier of the Institut Gustave Roussy in France reported that the median overall survival for patients treated with sunitinib was 26.0 months while the median overall survival for those treated with the immunotherapy combination was not yet reached. Dr. Escudier was also an investigator on the study.

“We have seen a significant improvement in overall survival,” Dr. Motzer said in an interview, with a caveat. “The data must continue to be looked at carefully to determine which patients will do better with ipilimumab and nivolumab and which might do better with sunitinib.”

Kristina’s Story
Learn how surgery and a clinical trial helped Kristina overcome stage IV kidney cancer.
Learn more

He said that there was a clear benefit for the combination among people with poor- and intermediate-risk renal cell carcinoma in extending overall survival and reducing tumor size. However, a small group of patients with favorable risk did see a higher rate of tumor shrinkage with sunitinib.

Dr. Motzer highlighted the fact that the immunotherapy combination works completely differently from sunitinib and provides a better chance for longer survival for patients who have not yet been treated — what is known as first-line therapy, a crucial area of unmet need.

“It’s a completely different mechanism of action and it introduces a new type of therapy in this setting,” Dr. Motzer says. “And with the exception of one trial many years back, we haven’t been able to demonstrate survival benefit in first-line therapy for renal cell carcinoma.”

Because the drugs work differently, the side effects are different too, said Dr. Motzer. The possible side effects seen with immunotherapies are inflammation of the lungs as well as the bowel, which can lead to diarrhea; skin rashes; and more.

“At MSK, we have extensive experience in treating patients with immunotherapies — with kidney cancer, melanoma, and beyond — and handling immune-related side effects,” he said.

Dr. Motzer found it important to consider the larger context of this one trial.

“This combination was initially developed here at MSK by [cancer immunologist] Jedd Wolchok in melanoma and it’s now the standard of care in that disease,” he said. “We’re following the same path in kidney cancer now.”

The phase III study of ipilimumb and nivolumab was supported by Bristol-Myers Squibb, the manufacturer of the two drugs.

Comments

i do understand that the purpose of this phase 3 trial was to compare combined immunotherapy against sunitinib. here's what i don't understand: why not a three-drug cocktail and sunitinib (it seems to work better with some people) and also include the two immunotherapy drugs used in your trial?

Dear Alan, we sent your question to Dr. Motzer, who explained that sunitinib has been combined with nivolumab, and the combination was felt to have too many side effects. Therefore, combining these three drugs is not recommended, nor is it under study in clinical trials. Thank you for your comment, and best wishes to you.

With metastatic HLRCC, would this combination be an option at some point if disease progresses? Diagnosed 3 1/2 years ago , have been on Opdivo in the past.

Add new comment

We welcome your questions and comments. While we share many of them with our world-class doctors and researchers, we regret that in order to protect your privacy, we are not able to make personal medical recommendations on this forum, nor do we publish comments that contain your personal information. If you would like to consult with an MSK doctor, we encourage you to make an appointment at 800-525-2225 or request an appointment online.

Your email address is kept private and will not be shown publicly.